Surgery in the Era of Molecular Medicine: Review of Gastroenteropanreatic Neuroendocrine Tumours
DOI:
https://doi.org/10.17140/SROJ-4-121Keywords:
Neuroendocrine tumour, Neuroendocrine neoplasm, Carcinoids, NETs, GEP-NETs, Molecular medicine eraAbstract
The management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) has evolved rapidly in the last two decades. Therefore, it is important that surgeons practicing in molecular medicine era have a clear understanding of the ever-changing landscape in GEP-NETs treatment and specifically how it influences the thinking and concepts of surgical treatment and research, in the context of transdisciplinary management.
References
Oberndorfer S. Karzinoide tumoren des dunndarms [In German]. Frankfurt Z Pathol . 1907: 426-432.
WHO. Neuroendocrine Tumour Grading System. 2017. Web site. http://www.agps.org.au/resources/AGPS_AGM_pro-grams/2016_AGM_presentations/Gill_WHO%202017%20 Neuroendocrine%20October%2027.pdf. Accessed June 25, 2017.
Nishikura K, Watanabe H, Iwafuchi M, Fujiwara T, Kojima K, Ajioka Y. Carcinogenesis of gastric endocrine cell carcino-ma: Analysis of histopathology and p53 gene alteration. Gastric Cancer. 2003; 6(4): 203-209. doi: 10.1007/s10120-003-0249-0
Buettner M, Dimmler A, Magener A, et al. Gastric PDX-1 ex-pression in pancreatic metaplasia and endocrine cell hyperplasia in atropic corpus gastritis. Mod Pathol. 2004; 17(1): 56-61. doi: 10.1038/sj.modpathol.3800015
Michalopoulos N, Papavramidis TS, Karayannopoulou G, et al. Neuroendocrine tumours of extrahepatic biliary tract. Pathol Oncol Res. 2014: 20(4): 765-775. doi: 10.1007/s12253-014- 9808-4
Noronha YS, Raza AS. Well differentiated neuroendocrine carcinoid_ tumours of the extrahepatic biliary ducts. Arch Pathol Lab Med. 2010; 134(7): 1075-1079. doi: 10.1043/2008- 0764-RS.1
Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-pro-ducing neuroendocrine tumours of the duodenum and pancreas: Incidence, types, biologic behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008; 15(1): 229-241. doi: 10.1677/ERC-07-0157
Dayal Y, Tallberg KA, Nunnemacher G, DeLellis RA, Wolfe HJ. Duodenal carcinoids in patients with and without neurofi-bromatosis. A comparative study. Am J Surg Pathol. 1986; 10 (5): 348-357.
Öberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005; 19(5): 753-781. doi:
1016/j.bpg.2005.06.002 10. Shi C, Klimstra DS. Pancreatic neuroendocrine tumours: Pathologic and molecular characteristics. Semin Diagn Pathol. 2014; 31(6): 498-511. doi: 10.1053/j.semdp.2014.08.008
Deschamps L, Couvelard A. Endocrine tumours of the ap-pendix: A pathologic review. Arch Pathol Lab Med. 2010; 134(6): 871-875. doi: 10.1043/1543-2165-134.6.871
Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE. Rectal carcinoids: The most frequent car-cinoid tumor. Dis Colon Rectum. 1992; 35 (8): 717-725. doi: 10.1007/BF02050318
Levy AD, Sobin LH. From the archives of the AFIP. Gas-trointestinal carcinoids: Imaging features with clinicopathologic comparison. Radiographics. 2007; 27(1): 237-257. doi: 10.1148/ rg.271065169
Kim JY, Kim KS, Kim KJ, et al. Non-L cell immunopheno-type and large tumour size in rectal neuroendocrine tumours are associated with aggressive clinical bahaviour and worse prog-nosis. Am J Surg Pathol. 2015; 39(5): 632-643. doi: 10.1097/ PAS.0000000000000400
Sohn JH, Cho MY, Park Y, et al. Prognostic significance of defining L-cell type on the biologic behavior of rectal neuroen-docrine tumours in relation with pathological parameters. Can-cer Res Treat. 2015; 47(4): 813-822. doi: 10.4143/crt.2014.238
Campana D, Nori F, Piscitelli L, et al. Chromogranin A: Is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007; 25: 1967-1973. doi: 10.1200/JCO.2006.10.1535
Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tu-mours. A consensus statement on behalf of the European Neu-roendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80(6): 394-424. doi: 10.1159/000085237
Prommegger R, Obrist P, Ensinger C, et al. Retrospective evaluation of carcinoid tumours of the appendix in children. World J Surg. 2002; 26: 1489-1492. doi: 10.1007/s00268-002- 6440-3
Yamaguchi N, Isomoto H, Nishiyama H, et al. Endosscopic submucosal dissection for rectal carcinoid tumours. Surg Endosc. 2010; 24(3): 504-508. doi: 10.1007/s00464-009-0606-0
Rothmund M, Angelini L, Brunt M. et al. Surgery for benign insulinoma: An international review. World J Surg. 1990; 14(3): 393-399. doi: 10.1007/BF01658536
Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK. He-patic resection for metastatic neuroendocrine carcinomas. Am J Surg. 1995; 169(1): 36-43. doi: 10.1016/S0002-9610(99)80107- X
Le Treut P, Delpero JR, Dousset B, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: A 31-case French multicentric report. Ann Surg. 1997; 225(4): 355-364.
Le Treut YP, Gregoire E, Klempnauer J, et al. Liver trans-plantation for neuroendocrine tumours in Europe – results and trends in patient selection: A 213 case Europe Liver Transplant Registry study. Ann Surg. 2013; 257: 807-815. doi: 10.1097/ SLA.0b013e31828ee17c
Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorellius LE, Oberg KE. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer. 1998; 83: 2293-2301. doi: 10.1002/(SICI)1097- 0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E
Kennedy AS, Dezam WA, McNeillie P, et al. Radioem-bolization for unresectable neuroendocrine hepatic metasta-ses using resin 90Y-microspheres: Early results in 148 pa-tients. Am J Clin Oncol. 2008; 31: 271-279. doi: 10.1097/ COC.0b013e31815e4557
Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996; 334: 246-254. doi: 10.1056/ NEJM199601253340408
Caplin ME, Pavel M, Cwikla JB. Lanreotide in metastatic enteropancreatic neuroendocrine tumours. N Engl J Med. 2014; 371(3); 224-233. doi: 10.1056/NEJMoa1316158
Jacobsen MB, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuro-endocrine tumours. Report on a double-bind randomized trial. J Intern Med. 1995; 237(3): 369-275. doi: 10.1111/j.1365- 2796.1995.tb01175.x
Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double blind, prospective, randomized study on the effectofoctretide LAR in the control of tumour growth in pa-tients with metastatic neuroendocrine midgut tumours: A report from the PROMID Study Group. J Clin Oncol. 2009; 27: 4656- 4663. doi: 10.1200/JCO.2009.22.8510
O’Dorisio TM, Gaginella TS, Mekhjian HS, Rao B, O’Dorisio MS. Somatostatin and analogues in the treatment of VIPoma. Ann N Y Acad Sci. 1988; 527: 528-535. doi: 10.1111/ j.1749-6632.1988.tb27006.x
Kvols LK, Moertel CG, O’Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of long-acting so-matostatin analogue. N Engl J Med. 1986; 315: 663-666. doi: 10.1056/NEJM198609113151102
Schmid HA, Schoeffter P. Functional activity of the mul-tiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology. 2004; 80(Suppl 1): 47-50. doi: 10.1159/000080741
Eriksson B, Kloppel G, Krenning E, et al. Consensus guide-lines for the management of patients with digestive neuroendo-crine tumors – well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008; 87(1): 8-19. doi: 10.1159/000111034
Caplin M, Ruszniewski P, Pavel M, et al. A randomized, dou-ble-blind, placebo-Controlled study of Lanreotide Antiprolifera-tive Response in patients with gastroenteropancreatic Neuro En-docrine Tumors (CLARINET). Eur J Cancer. 2013; 49.
Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carci-noid tumors: A randomized trial. Ann Oncol. 1992; 3(8): 635- 638. doi: 10.1093/oxfordjournals.annonc.a058291
Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117(2): 268- 275. doi: 10.1002/cncr.25425
Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364: 501-513. doi: 10.1056/NEJMoa1003825
Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pan-creatic neuroendocrinetumors. N Engl J Med. 2011; 364: 514- 523. doi: 10.1056/NEJMoa1009290
Fuhrer DK, Kobayashi M, Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporine A are through regulation of the ATP-sensitive potassium channel. Dia-betes Obes Metab. 2001; 3(6): 393-402. doi: 10.1046/j.1463- 1326.2001.00150.x
Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006; 95(9): 1148- 1154. doi: 10.1038/sj.bjc.6603419
Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): A Phase II Consortium study. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part 1, 2007; 25(Suppl 18): 4504. doi: 10.1200/jco.2007.25.18_suppl.4504
Phan AT, Yao JC, Fogelman DR, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (santostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). J Clin Oncol. 2010; 28(Suppl 15): 4001.
Yao JC, Phan A, Hoff PM et al. Targeting vascular endothelial growth factor in advanced carcinoid tumour: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon akpha-2b. J Clin Oncol. 2008; 26: 1316-1323. doi: 10.1200/JCO.2007.13.6374
Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomized, placebo-controlled, phase 3 study. Lancet. 2011; 378: 2005-2012. doi: 10.1016/S0140- 6736(11)61742-X
Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro stud-ies of imatinib in advanced carcinoid tumour. Clin Cancer Res. 2007; 13(1): 234-240. doi: 10.1158/1078-0432.CCR-06-1618
Biesma B, Willemse PH, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: Effect on tumours and tumour markers. Br J Cancer. 1992; 66(5): 850- 855.
Oberg K. Interferons in the management of neuroendocrine tumours and their possible mechanism of action. Yale J Biol Med. 1992; 65: 519-529; discussion 531-536.
Oberg K, Eriksson B, Janson ET. Interferon alone or in com-bination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion. 1994; 3: 64-69. doi: 10.1159/000201204
Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Kren-ning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007; 21(1): 111-129. doi: 10.1016/j.beem.2007.01.007
Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treat-ment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124-2130. doi: 10.1200/JCO.2007.15.2553
Valkema R, Pauwels S, Kvols LK, et al. Survival and re-sponse after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenter-opancreatic neuroendocrine tumors. Semin Nucl Med. 2006; 3 6(2): 147-156. doi: 10.1053/j.semnuclmed.2006.01.001
Strosberg JR, Wolin EM, Chasen B, et al. NETTER-1 phase III: Progression-free surviva, radiographic response, and prelim-inary overall survival results in patients with midgut neuroendo-crine tumours treated with 177-Lu-Dotatate. J Clin Oncol. 2016; 34(4): 194-194. doi: 10.1200/jco.2016.34.4_suppl.194
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumours. N Engl J Med. 2017; 376(2): 125-135. doi: 10.1056/NEJMoa1607427
Rorstad O. Prognostic indicators for carcinoid neuroendo-crine tumors of the gastrointestinal tract. J Surg Oncol. 2005; 89(3): 151-160. doi: 10.1002/jso.20179
Halfdanarson TR, Rubin J, Farnell MB, et al. Pancreatic endocrine neoplasms: Epidemiology and prognosis of pancreatic endocrine tumors. Endocr Relat Cancer. 2008; 15(2): 409-427. doi: 10.1677/ERC-07-0221
Madeira I, Terris B, Voss M. et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998; 43: 422-427. doi: 10.1136/gut.43.3.422
Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factor and survival in 324 patients with pancreatic endocrine tumour treated at a single institution. Clin Cancer Res. 2008; 14: 7798-7803. doi: 10.1158/1078-0432.CCR-08-0734
Carty S, Jensen RT, Norton JA, et al. Prospective study of aggressive resection of metastatic pancreatic endocrine tumour. Surgery. 1992; 112(6): 1024-1031.
Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011; 29(7): 934-943. doi: 10.1200/JCO.2010.33.2056
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Surgical Research (SR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.